Japan’s IP office upholds CRISPR patent and allows third

A CRISPR patent filed by scientist Emmanuelle Charpentier alongside the Regents of the University of California and the University of Vienna (collectively known as CVC) has been upheld by the Japan Patent Office (JPO).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

Preliminary injunctions in pharmaceutical patent cases in Japan

23 January 2024 Five cases in which preliminary injunctions were granted are examined by Takanori Abe of Abe & Partners.

Asia

Japan: DOE and cross-border infringement of a biologics process patent

9 February 2023 The Tokyo District Court judgment on patent infringement and question of territoriality is game-changing, says Takanori Abe of Abe & Partners.

Biotechnology

Will authorised biologics deter biosimilars? Utilising JFTC’s expertise in drug pricing

8 March 2022 Should the MHLW and CSIMC consider competition in drug pricing, it would be necessary to formulate systems to utilise the expertise of a competition expert, namely the Japan Fair Trade Commission, says Takanori Abe of Abe & Partners.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Japan’s IP office upholds CRISPR patent and allows third

More on this story

Editor's picks

Editor's picks

More features